Department of Clinical Epidemiology, Leiden University Medical Center, PO Box 9600, 2333 ZA Leiden, The Netherlands.
Department of Cardiology, Willem Einthoven Center of Arrhythmia Research and Management, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Europace. 2022 Nov 22;24(11):1739-1753. doi: 10.1093/europace/euac096.
Multiple risk scores to predict ischaemic stroke (IS) in patients with atrial fibrillation (AF) have been developed. This study aims to systematically review these scores, their validations and updates, assess their methodological quality, and calculate pooled estimates of the predictive performance.
We searched PubMed and Web of Science for studies developing, validating, or updating risk scores for IS in AF patients. Methodological quality was assessed using the Prediction model Risk Of Bias ASsessment Tool (PROBAST). To assess discrimination, pooled c-statistics were calculated using random-effects meta-analysis. We identified 19 scores, which were validated and updated once or more in 70 and 40 studies, respectively, including 329 validations and 76 updates-nearly all on the CHA2DS2-VASc and CHADS2. Pooled c-statistics were calculated among 6 267 728 patients and 359 373 events of IS. For the CHA2DS2-VASc and CHADS2, pooled c-statistics were 0.644 [95% confidence interval (CI) 0.635-0.653] and 0.658 (0.644-0.672), respectively. Better discriminatory abilities were found in the newer risk scores, with the modified-CHADS2 demonstrating the best discrimination [c-statistic 0.715 (0.674-0.754)]. Updates were found for the CHA2DS2-VASc and CHADS2 only, showing improved discrimination. Calibration was reasonable but available for only 17 studies. The PROBAST indicated a risk of methodological bias in all studies.
Nineteen risk scores and 76 updates are available to predict IS in patients with AF. The guideline-endorsed CHA2DS2-VASc shows inferior discriminative abilities compared with newer scores. Additional external validations and data on calibration are required before considering the newer scores in clinical practice.
ID CRD4202161247 (PROSPERO).
已经开发出多种预测房颤(AF)患者缺血性脑卒中(IS)的风险评分。本研究旨在系统地回顾这些评分及其验证和更新情况,评估其方法学质量,并计算预测性能的汇总估计值。
我们在 PubMed 和 Web of Science 上搜索了用于开发、验证或更新 AF 患者 IS 风险评分的研究。使用预测模型风险偏倚评估工具(PROBAST)评估方法学质量。为了评估区分度,使用随机效应荟萃分析计算了汇总的 c 统计量。我们确定了 19 个评分,其中 70 项研究对其进行了验证,40 项研究对其进行了更新,分别包括 329 次验证和 76 次更新,几乎都是针对 CHA2DS2-VASc 和 CHADS2。在 6267728 名患者和 359373 例 IS 事件中计算了汇总的 c 统计量。对于 CHA2DS2-VASc 和 CHADS2,汇总的 c 统计量分别为 0.644(95%置信区间[CI]:0.635-0.653)和 0.658(0.644-0.672)。新的风险评分具有更好的区分能力,改良-CHADS2 的区分能力最佳[c 统计量 0.715(0.674-0.754)]。仅对 CHA2DS2-VASc 和 CHADS2 进行了更新,显示出了更好的区分能力。校准是合理的,但只有 17 项研究提供了相关数据。PROBAST 表明所有研究都存在方法学偏倚的风险。
有 19 个风险评分和 76 个更新版本可用于预测 AF 患者的 IS。与较新的评分相比,指南认可的 CHA2DS2-VASc 显示出较差的区分能力。在考虑将新评分应用于临床实践之前,还需要进行更多的外部验证和校准数据。
ID CRD4202161247(PROSPERO)。